[go: up one dir, main page]

UA6098A1 - Method for preventing development of pulmonary tuberculosis - Google Patents

Method for preventing development of pulmonary tuberculosis

Info

Publication number
UA6098A1
UA6098A1 UA4298215A UA4298215A UA6098A1 UA 6098 A1 UA6098 A1 UA 6098A1 UA 4298215 A UA4298215 A UA 4298215A UA 4298215 A UA4298215 A UA 4298215A UA 6098 A1 UA6098 A1 UA 6098A1
Authority
UA
Ukraine
Prior art keywords
thymalin
dose
pulmonary tuberculosis
preventing development
level
Prior art date
Application number
UA4298215A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Катерина Федорівна Чернушенко
Екатерина Федоровна Чернушенко
Любов Соломонівна Когосова
Любовь Соломоновна Когосова
Іван Григорович Ільницький
Иван Григорьевич Ильницкий
Сусана Ісаівна Гончарова
Сусана Исаевна Гончарова
Микола Микитович Коваленко
Николай Никитович Коваленко
Олександр Юхимович Марков
Александр Ефимович Марков
Вікторія Павлівна Костроміна
Виктория Павловна Костромина
Людмила Всеволодівна Кучугура-Кучеренко
Людмила Всеволодовна Кучугура-Кучеренко
Оксана Романівна Панасюкова
Оксана Романовна Панасюкова
Hаталія Дмитрівна Башкірова
Original Assignee
Український Науково-Дослідний Інститут Фтизіатрії І Пульмонології Ім. Акад. Ф.Г. Яновського
Украинский научно-исследовательский институт фтизиатрии и пульмонологии им.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Український Науково-Дослідний Інститут Фтизіатрії І Пульмонології Ім. Акад. Ф.Г. Яновського, Украинский научно-исследовательский институт фтизиатрии и пульмонологии им. filed Critical Український Науково-Дослідний Інститут Фтизіатрії І Пульмонології Ім. Акад. Ф.Г. Яновського
Priority to UA4298215A priority Critical patent/UA6098A1/en
Publication of UA6098A1 publication Critical patent/UA6098A1/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The method comprises the use of chemotherapeutics and the immune correcting agent, namely thymalin. The dose and the schedule of thymalin administration are assessed according to the level of Ea-rosette forming cells. The level increased at least by 20% in the presence of thymalin at a dose of at least 2 g/mL requires the dose of 5 mg twice a week. If the reaction increases only upon the addition of 20 g/mL of thymalin, the daily dose of 20 mg is required.
UA4298215A 1987-08-17 1987-08-17 Method for preventing development of pulmonary tuberculosis UA6098A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UA4298215A UA6098A1 (en) 1987-08-17 1987-08-17 Method for preventing development of pulmonary tuberculosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UA4298215A UA6098A1 (en) 1987-08-17 1987-08-17 Method for preventing development of pulmonary tuberculosis

Publications (1)

Publication Number Publication Date
UA6098A1 true UA6098A1 (en) 1994-12-29

Family

ID=74575299

Family Applications (1)

Application Number Title Priority Date Filing Date
UA4298215A UA6098A1 (en) 1987-08-17 1987-08-17 Method for preventing development of pulmonary tuberculosis

Country Status (1)

Country Link
UA (1) UA6098A1 (en)

Similar Documents

Publication Publication Date Title
EP0136011A3 (en) A method of hormonal treatment of peri-menopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
ZA897977B (en) Contraception system and method
ES8402155A1 (en) Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
AU7567587A (en) Dosage form for delivering acid sensitive beneficial agent
GEP20043290B (en) Anti-Estrogen Plus Progestin Containing Oral Contraceptives
NO20083842L (en) Use of soluble lymphotoxin-beta receptor for drug preparation
ES8600060A1 (en) Galenic form for the administration by inhalation of calcium antagonists.
ATE220321T1 (en) ORAL DOSAGE FORMS CONTAINING SOLID FLUPIRTINE WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS
ES8702427A1 (en) 2-Substituted-1,3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them.
DE2963990D1 (en) Analgesic tablet and process for its preparation
ES8801912A1 (en) Substituted benzopyrans, process for their preparation and their use in medicines.
IE42950L (en) X-ray contrast preparations
IE822064L (en) Composition containing human insulin and c-peptide
EP0019403A3 (en) Hydroxyalkyl-starch drug carrier and method of administering a biologically active compound to an animal
ES8605676A1 (en) Oral sustained-release acetylsalicylic-acid formulations.
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
PT81033A (en) Process for preparing 2,3-dihydrobenzofuran-5-sulfonamide derivatives
JPS5767518A (en) Radiosensitizing agent or agent for increasing effect of radiomimetic substance
ES8705763A1 (en) Pharmaceutical compositions containing gels.
ES8502440A1 (en) New azepinoindoles, their production and pharmaceutical compositions containing them
UA6098A1 (en) Method for preventing development of pulmonary tuberculosis
DE3380166D1 (en) Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction
DE2963545D1 (en) Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation
GB1503856A (en) Pharmaceutical composition containing trimethoprim sulphamethoxazole and alpha-amylase
GB1535778A (en) Compounds useful in treatment of unipolar depression